Search

Sana Biotechnology Inc

Geschlossen

BrancheGesundheitswesen

3.83 -2.05

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

3.83

Max

3.87

Schlüsselkennzahlen

By Trading Economics

Einkommen

-16M

-64M

EPS

-0.13

Angestellte

142

EBITDA

-17M

-61M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+107.79% upside

Dividenden

By Acuity

Nächstes Ergebnis

4. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

274M

1.2B

Vorheriger Eröffnungskurs

5.88

Vorheriger Schlusskurs

3.83

Nachrichtenstimmung

By Acuity

25%

75%

37 / 339 Ranking in Healthcare

Sana Biotechnology Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

4. Sept. 2026, 20:07 UTC

Sana Biotechnology Inc shares are lower amid broader market pressures following a strong jobs report, with no specific company news identified.

2. Sept. 2026, 20:08 UTC

Social Media
News

Sana Biotechnology Inc is advancing today amid gains in the Biotechnology sector and upcoming investor conferences focused on engineered cell therapies.

31. Aug. 2026, 20:07 UTC

Sana Biotechnology Inc. shares decline today, continuing a trend since Friday's close, amid broader market pressures from rising interest rate expectations.

28. Aug. 2026, 23:56 UTC

Sana Biotechnology Inc. shares advanced modestly higher in after-market trading, remaining near the upper end of their one-month range.

27. Aug. 2026, 23:02 UTC

Sana Biotechnology shares declined in after-market trading, reflecting a notable drop since Thursday's close, despite earlier gains earlier in the session.

26. Aug. 2026, 19:46 UTC

Sana Biotechnology Inc shares are higher today, trading near the upper end of their one-month range and above the 20-day moving average.

25. Aug. 2026, 23:16 UTC

Sana Biotechnology Inc shares are lower in after-market hours. Market sentiment was affected by a sharp decline in crude oil prices.

24. Aug. 2026, 19:36 UTC

Correlated Moves

Sana Biotechnology Inc's shares are lower today, reflecting broader declines in the biotech sector, including a drop in the ARK Genomic Revolution ETF.

21. Aug. 2026, 23:36 UTC

Sana Biotechnology Inc. shares moved lower in after-market trading, despite resilience in major stocks like Tesla and UnitedHealth. The price remains above its 20-day moving average.

20. Aug. 2026, 23:01 UTC

Sana Biotechnology Inc. shares are higher in after-hours trading, driven by gains in the Biotechnology sub-sector and remaining above its 20-day moving average.

19. Aug. 2026, 23:06 UTC

Sana Biotechnology Inc shares are lower in after-market hours, following a notable decline from earlier highs. No specific news was identified to explain the move.

18. Aug. 2026, 19:46 UTC

Sana Biotechnology Inc. shares are lower today, reflecting a decline since Monday amid rising Treasury yields and ongoing inflation concerns.

17. Aug. 2026, 23:46 UTC

Sana Biotechnology Inc shares are slightly higher in after-market hours. No specific news was identified to explain the movement.

14. Aug. 2026, 20:06 UTC

News

Sana Biotechnology shares declined amid mixed analyst ratings and broader market challenges, with BofA lowering its price target to $6.00 from $7.00.

13. Aug. 2026, 19:36 UTC

Sana Biotechnology Inc shares are lower today, continuing a decline since Wednesday. The price remains above its 20-day moving average.

12. Aug. 2026, 23:46 UTC

Sana Biotechnology Inc shares are lower in after-market hours, with no specific news identified to explain the price movement.

11. Aug. 2026, 19:31 UTC

News

Sana Biotechnology shares are higher following Q2 results showing an adjusted EPS of -$0.13, exceeding estimates, and a $25 million investment from Mayo Clinic.

10. Aug. 2026, 23:01 UTC

News

Sana Biotechnology Inc shares are lower in after-market hours following a second-quarter loss of $63.6 million, despite an adjusted EPS that exceeded expectations.

7. Aug. 2026, 19:56 UTC

Sana Biotechnology Inc. shares are higher, supported by broader market dynamics following a disappointing jobs report easing interest rate concerns.

5. Aug. 2026, 19:56 UTC

Sana Biotechnology Inc. is trading higher during Wednesday's session, having peaked earlier before pulling back slightly while remaining above its 20-day moving average.

4. Aug. 2026, 20:05 UTC

Sana Biotechnology Inc shares are higher, reflecting strong performance amid a decline in crude oil prices, which may ease inflationary pressures.

3. Aug. 2026, 19:46 UTC

Sana Biotechnology Inc is higher today, benefiting from a broader market rally, particularly in technology, despite earlier session pullbacks.

31. Juli 2026, 23:06 UTC

Sana Biotechnology Inc shares are lower in after-market hours, retracing from earlier gains. Broader market trends show mixed sentiment among major tech firms.

30. Juli 2026, 19:29 UTC

Sana Biotechnology Inc shares are higher today, recovering from earlier lows. The stock has shown an upward trend since Wednesday's close.

29. Juli 2026, 23:36 UTC

Sana Biotechnology Inc shares are higher in after-market hours, reflecting a slight increase since Wednesday's close amid routine market activity and broader volatility.

28. Juli 2026, 18:03 UTC

Sana Biotechnology Inc. shares are higher as biotechnology stocks advance, though they diverge from a recent trend of daily gains since Monday's close.

27. Juli 2026, 19:07 UTC

Sana Biotechnology Inc shares are higher today, continuing a rally since Friday. No specific news has been identified to explain the price movement.

24. Juli 2026, 18:26 UTC

Sana Biotechnology Inc. shares are trading lower amid broader market volatility, with no specific company news identified to explain the decline.

22. Juli 2026, 19:36 UTC

News

Sana Biotechnology has shifted focus to B-cell autoimmune disorders amid competition in oncology. Shares are higher since Tuesday, supported by rising crude oil prices.

20. Juli 2026, 17:56 UTC

Social Media

Sana Biotechnology Inc shares are lower, continuing a nine-session decline. Social media discussions raise skepticism about the timeline for its allogeneic cell therapies.

Peer-Vergleich

Kursveränderung

Sana Biotechnology Inc Prognose

Kursziel

By TipRanks

107.79% Vorteil

12-Monats-Prognose

Durchschnitt 8 USD  107.79%

Hoch 12 USD

Tief 6 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Sana Biotechnology Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

5 ratings

5

Buy

0

Halten

0

Sell

Stimmung

By Acuity

37 / 339 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
help-icon Live chat